FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes

Lexicon Pharmaceuticals

31/10/2024 20:47

Oct 31 (Reuters) - Independent advisers to the U.S. Food
and Drug Administration on Thursday voted against recommending
Lexicon Pharmaceuticals'  LXRX.O  add-on treatment to insulin
therapy for managing blood glucose levels in adults with type 1
diabetes and chronic kidney disease.
    The panel voted 13 to 3 against recommending the drug,
chemically known as sotagliflozin.

 (Reporting by Sneha S K and Sruthi Narasimha Chari in
Bengaluru; Editing by Shailesh Kuber)
 ((Sneha.SK@thomsonreuters.com;))